Table 1.
Characteristics of VA Patients Living With HIV: CD4 and Viral Load Samples with Comparison to Total Study Sample*
| CD4 Sample N= 21,999 | Viral Load Sample N=22,143 | Total Study Sample* N = 33,224 | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | N | (%) | p-value** | N | (%) | p-value** | N | (%) |
| Demographics | ||||||||
| Gender (Female) | 606 | (2.8) | 0.011 | 613 | (2.8) | 0.02 | 971 | (2.9) |
| Age | <0.001 | <0.001 | ||||||
| <50 | 7,763 | (35.3) | 7,837 | (35.4) | 11,661 | (35.1) | ||
| 50—64 | 12,071 | (54.9) | 12,136 | (54.8) | 17,963 | (54.1) | ||
| ≥65 | 2,165 | (9.8) | 2,170 | (9.8) | 3,600 | (10.8) | ||
| Race/Ethnicity | <0.001 | <0.001 | ||||||
| Black | 10,676 | (48.5) | 10,741 | (48.5) | 16,028 | (48.2) | ||
| Hispanic | 1,870 | (8.5) | 1,880 | (8.5) | 2,691 | (8.1) | ||
| White | 8,864 | (40.3) | 8,916 | (40.3) | 13,346 | (40.2) | ||
| Other/Unknown | 589 | (2.7) | 606 | (2.7) | 1,159 | (3.5) | ||
| MH and SUD | ||||||||
| Depressive Disorder | 6,639 | (30.2) | <0.001 | 6,658 | (30.1) | <0.001 | 9,502 | (28.6) |
| Anxiety Disorder | 1,951 | (8.9) | 0.005 | 1,952 | (8.8) | 0.02 | 2,845 | (8.6) |
| Serious Mental Illness | 2,127 | (9.7) | 0.36 | 2,125 | (9.6) | 0.80 | 3,177 | (9.6) |
| Stimulant Use Disorder | 332 | (1.5) | 0.008 | 332 | (1.5) | 0.003 | 461 | (1.4) |
| Opioid Use Disorder | 807 | (3.7) | <0.001 | 811 | (3.7) | <0.001 | 1,325 | (4.0) |
| Other Drug Use Disorder | 1,654 | (7.5) | 0.04 | 1,653 | (7.5) | 0.01 | 2,570 | (7.7) |
| HIV Clinical Measure | ||||||||
| On antiretroviral therapy (ART) at Baseline | 16,690 | (75.9) | <0.001 | 16,761 | (75.7) | <0.001 | 21,080 | (63.5) |
| Mean ART Adherence (SD) | 81.2 | (24.4) | <.001 | 82.7 | (23.4) | <.001 | 79.1# | (26.2) |
| Detectable Viral Load | 4,581 | (23.5) | <.001 | 4,624 | (23.6) | <.001 | 6,650 | (26.2) |
| Alcohol Use Severity | ||||||||
| Alcohol Use Disorder | 3,061 | (13.9) | 0.009 | 3,053 | (13.8) | <0.001 | 4,742 | (14.3) |
| Alcohol-Specific Condition | 102 | (0.5) | <.001 | 104 | (0.5) | <.001 | 213 | (0.6) |
| Baseline AUDIT-C Category | <0.001 | <0.001 | ||||||
| 0 | 10,372 | (47.2) | 10,434 | (47.1) | 15,563 | (46.8) | ||
| 1–3 (1–2 for women) | 8,760 | (39.8) | 8,828 | (39.9) | 12,988 | (39.1) | ||
| 4–5 (3–5 for women) | 1,676 | (7.6) | 1,705 | (7.7) | 2,612 | (7.9) | ||
| 6–7 | 512 | (2.3) | 502 | (2.3) | 854 | (2.6) | ||
| 8–12 | 679 | (3.1) | 674 | (3.0) | 1,207 | (3.6) | ||
*
Total Study Sample includes all in the eligible HIV+ sample who had at least one AUDIT-C screen
**
all p-values reflect comparison between those who did and did not meet criteria for the analytic samples out of those in the Total Study Sample (e.g., comparison of those 21,999 in the CD4 analytic sample to the 11,225 not in CD4 analytic sample)
#
N=21,080 patients prescribed ART